Where does Prevail Therapeutics, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Prevail Therapeutics, Inc. ranks #23,235 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Prevail Therapeutics, Inc. hold?

Prevail Therapeutics, Inc. holds 12 US utility patents granted between 2020 and 2024, spanning 8 technology areas.

What is Prevail Therapeutics, Inc.'s Innovation Score?

Prevail Therapeutics, Inc. has an Innovation Score of 51.9 out of 100 (top 11% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Prevail Therapeutics, Inc. focus on?

Prevail Therapeutics, Inc.'s top technology area is C12Y (Enzymes) with 11 patents, ranking #239 of 1,675 assignees active in that subclass. Grants appear in 8 CPC subclasses total.

Is Prevail Therapeutics, Inc.'s patent grant rate increasing or decreasing?

Insufficient historical data is available to calculate a velocity trend for Prevail Therapeutics, Inc..

What does claim depth mean for Prevail Therapeutics, Inc.'s patents?

Prevail Therapeutics, Inc.'s patents average 21.8 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Prevail Therapeutics, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Prevail Therapeutics, Inc.

USPTO PatentsView assignee record - 12 granted patents across 8 technology areas, recorded in grant years 2020–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C12Y (Enzymes).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Prevail ranks #23,235 of 49,997 tracked US assignees by granted-patent volume, with 12 patents across 8 technology areas.

#23,235
of 49,997 US assignees by volume: Top 11%
by Innovation Score (51.9/100): 21.8
avg claims per patent

USPTO PatentsView assignee plate

Corpus R23235 · US Corporation #23,235 · 12 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-DENSE · TYPE-USCORP · SPAN-YRS · BOOK-RICH

GRANTS-MICRO 12 grants
MID-PACK #23,235/49,997
PHOTO-FINISH Pregis Intellipack
CPC-NARROW C12Y · 8 areas
INNOV-PAR 51.9/100
CLAIMS-DENSE 21.8 claims/avg
TYPE-USCORP US Corporation
SPAN-YRS 2020–2024 · 5y
BOOK-RICH 9/10 fields

Nearest grant-volume peer: Pregis Intellipack LLC (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Prevail’s 51.9 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 8.9 pts (17%) Velocity 20.0 pts (38%) Breadth 10.0 pts (19%) Claim depth 13.1 pts (25%)

Qualcomm Incorporated · highest

85
Prevail Therapeutics · this assignee

52
3D Lighting… · lowest

7

What this shows Prevail's Innovation Score is 51.9/100 (top 11% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Prevail?

Each dot is one of Prevail’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Prevail’s own 21.8 claims/patent is ABOVE the 12.8 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Prevail vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Prevail's grants concentrate

Prevail Therapeutics, Inc. is a focused PatentsView assignee: 8 CPC subclasses with 91.7% of grants classified under C12Y (Enzymes). Peak complete grant year is 2023 (5 grants) versus a trough of 1 in 2021. By volume, Prevail sits between Pregis Intellipack LLC and Prolacta Bioscience, Inc..

Prevail's three-year grant acceleration

Prevail Therapeutics, Inc. shows 9 grants in 2022–2024 against only 3 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Pregis Intellipack

12
Premium Genetics…

12
Present Arms

12
Presidio Componen…

12
Primed Halberstad…

12
Prinsco

12
Probiora Health

12
Prolacta Bioscien…

12
Prevail Therapeut… ◀

12

What this shows Prevail holds 12 patents at rank #23,231, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Prevail

By rank, the assignees closest to #23,231 in granted patent volume.

Leaders in C12Y (Enzymes)

Other assignees with the most granted patents in Prevail's primary technology class.

Prevail's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

52 Top 11% higher than 89% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2020–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2020–2019 baseline. Full figures in the table below.

View data table

Prevail Therapeutics, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2020	2	16.7%
2021	1	8.3%
2023	5	41.7%
2024	4	33.3%

Which technologies does Prevail Therapeutics, Inc. patent most?

C12Y - Enzymes 11

C07K - Peptides 11

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 11

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 11

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 8

A01K - Animal HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; Rearing OR Breeding Animals, NOT Otherwise Provided FOR; NEW Breeds OF Animals 5

C07H - SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids 4

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 1

Top 8 of 8 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Prevail Therapeutics, Inc.'s patent record in context - here's where to go next.

Prevail Therapeutics, Inc.'s lead technology class is C12Y (Enzymes), 91.7% of its portfolio - see every assignee active in that class. Explore C12Y
Ranked #23,235 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Prevail Therapeutics, Inc. against Pregis Intellipack LLC, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 51.9/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.